Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-14
2010-02-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S343000, C514S406000, C544S141000, C544S372000, C546S278400, C548S364100
Reexamination Certificate
active
07666868
ABSTRACT:
Compounds of a certain formula (I)in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
REFERENCES:
patent: 4960787 (1990-10-01), Wasley
patent: 5534654 (1996-07-01), Ohtani et al.
patent: 6432999 (2002-08-01), Talley et al.
patent: 2002/0026052 (2002-02-01), Boschelli et al.
patent: 2005/0234033 (2005-10-01), Anandan et al.
patent: 2005/0288282 (2005-12-01), Delorme et al.
patent: 2006/0258728 (2006-11-01), Tani et al.
patent: 2007/0184979 (2007-08-01), Maier et al.
patent: 0 570 594 (1993-11-01), None
patent: 1 431 267 (2004-06-01), None
patent: 9312075 (1993-06-01), None
patent: 01/38322 (2001-05-01), None
patent: 0138323 (2001-05-01), None
patent: 03016254 (2003-02-01), None
patent: 03/024448 (2003-03-01), None
patent: 2004/037751 (2004-05-01), None
patent: 2004/046094 (2004-06-01), None
patent: 2005/020921 (2005-03-01), None
patent: 2005/070900 (2005-08-01), None
patent: 2005/086898 (2005-09-01), None
patent: 2005/087724 (2005-09-01), None
patent: PCTEP2005051086 (2005-10-01), None
patent: 2006066189 (2006-06-01), None
patent: PCTEP2006003171 (2006-08-01), None
patent: 2006097474 (2006-09-01), None
patent: 2006/105979 (2006-10-01), None
patent: PCTEP2006066197 (2006-12-01), None
patent: 2007039404 (2007-04-01), None
Almenara, J., et al., “Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)”, Leukemia, vol. 16, pp. 1331-1343, (2002).
Angle, S. R., et al., “A Simple Method for the Synthesis of Substituted Benzylic Ketones: Homologation of Aldehydes via the in Situ Generation of Aryldiazomethanes from Aromatic Aldehydes”, J. Org. Chem., vol. 65, pp. 6458-6461, (2000).
Bouchain, G., et al., “Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors”, J. Med. Chem., vol. 46, pp. 820-830, (2003).
Chung, Y-L., et al., “A Therapeutic Strategy Uses Histone Deacetylase Inhibitors to Modulate the Expression of Genes Involved in the Pathogenesis of Rheumatoid Arthritis”, Molecular Therapy, vol. 8, pp. 707-717, (2003).
Dhordain, P., et al., “The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression”, Nucleic Acids Research, vol. 26, pp. 4645-4651, (1998).
Engman, L., et al., “Tetrahydrofuran Derivatives from Epoxides via Group Transfer Cyclization or Reductive Radical Cyclization of Organotellurium and Organoselenium Intermediates”, J. Org. Chem., vol. 62, pp. 157-173, (1997).
Fischle, W., et al., “Enzymatic Activity Associated with Class II HDACs is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR”, Molecular Cell., vol. 9, pp. 45-47, (2002).
Gao, L., et al., “Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family”,Journal Biol. Chem., vol. 277, pp. 25748-25755, (2002).
George, P., et al., “Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3”, Blood, vol. 105, pp. 1768-1777, (2005).
Glaser, K. B., et al., “Role of Class I and Class II histone deacetylase in carcinoma cells using siRNA”, Biochemical an Biophysical Research Communications, vol. 31, pp. 529-536, (2003).
Haggarty, S., et al., “Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation”, J. Proc. Natl. Acad. Sci. USA, vol. 100, pp. 4389-4394, (2003).
He, L. Z., et al., “Distinct Interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL”, Nature Genetics, vol. 18, pp. 126-135, (1998).
Hockly, E., et al., “Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease”, Proc. Natl. Acad. Sci. USA, vol. 100, pp. 2041-2046, (2003).
Johnstone, W. R., et al., “Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?”, Cancer Cell., vol. 4, pp. 13-18, (2003).
Kelly, W. K., et al., “Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients with Advanced Cancer”, J. Clin. Oncol., vol. 23, pp. 3923-3931, (2005).
Khochbin., S., et al., “Functional significance of histone deacetylase diversity”, Current Opinion Gen. Dev., vol. 11, pp. 162-166, (2001).
Kim, M. S., et al., “Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA”, Cancer Research, vol. 63, pp. 7291-7300, (2003).
Kraemer, O. H., et al., “Histone deacetylase as a therapeutic target”, Trends Endocrin. Metabol., vol. 12, pp. 294-300, (2001).
Lagger, G., et al., “Essential Function of histone deacetylase 1 in proliferation control and CDK inhibitor repression”, EMBO, vol. 21, pp. 2672-2681, (2002).
Leoni, F., et al., “The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines”, Proc. Natl., Acad. Sci. USA, vol. 99, pp. 2995-3000, (2002).
Mai, A., et al., “3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures”, J. Med. Chem., vol. 46, pp. 512-524, (2003).
Mai, A., et al., “3-(4-Aroyl-1-methy1-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity”, Journal Medicinal Chem., vol. 47, pp. 1098-1109, (2004).
Marks, P. A., et al., “Histone Deacetylases and Cancer: Causes and Therapies”, Nature Reviews Cancer, vol. 1, pp. 194-202, (2001).
Miller, T., et al., “Patent status of histone deacetylase inhibitors”, Expert Opin. Ther. Patents, vol. 14, pp. 791-804, (2004).
Miller, T. A., et al., “Histone Deacetylase Inhibitors”, Journal Med. Chem., vol. 46, pp. 5097-5116, (2003).
Mishra, N., et al., “Histone deacetylase inhibitors modulate renal disease in the MRL-1pr mouse”, Journal Clinical Invest., vol. 111, pp. 539-552, (2003).
Mitsiades, C. S., et al., “Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications”, PNAS, vol. 101, pp. 540-546, (2004).
Munster, R. N., et al., “The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells”, Cancer Research, vol. 61, pp. 8492-8497, (2001).
Murata, T., et al., “Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome”, Human Molecular Genetics, vol. 10, pp. 1071-1076, (2001).
Nakayama, T., et al., “Epigenetic Regulation of Androgen Receptor Gene Expression in Human Prostate Cancers”, Laboratory Inv., vol. 80, pp. 1789-1796, (2000).
Nimmanapalli, R., et al., “Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Ber-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells,” Cancer Research, vol. 63, pp. 5126-5315, (2003).
Nishida, K., et al., “Histone Deacetylase Inhibitor Suppression of Autoantibody-Mediated Arthritis in Mice via Regulation of p16INK4a and p21WAF/Cip1 Expression”, Arthritis Rheumatism, vol. 50, pp. 3365-3376, (2004).
Piekarz, R. L., et al., “Inhibitor of histone deacetylation, depsipeptid
Bär Thomas
Beckers Thomas
Gekeler Volker
Maier Thomas
Schneider Siegfried
4SC AG
Millen White Zelano & Branigan P.C.
Saeed Kamal A
Shterengarts Samantha L
LandOfFree
N-sulphonylpyrroles and their use as histone deacetylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-sulphonylpyrroles and their use as histone deacetylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-sulphonylpyrroles and their use as histone deacetylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161455